SCOTTSDALE, Ariz., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Reliance, Inc. (NYSE: RS) announced today that effective August 14, 2025, it has entered into a $400 million unsecured term loan facility maturing August 2028 (the “Facility”). The proceeds of the Facility were used to refinance the Company’s $400 million senior unsecured notes maturing August 15, 2025. The new Facility complements Reliance’s existing capital structure, further optimizing its balance sheet while maintaining ample capacity to invest in hig ...

Castellum, Inc. and Tradewinds Networks, Inc. Announce Execution of Reseller Agreement Castellum, Inc. (NYSE-American: CTM) and Tradewinds Networks, Inc. (“TNI”) jointly announce that CTM's newly formed product subsidiary, Castellum Advanced Technology Products, Inc., has entered into a reseller agreement with TNI to resell their products to Castellum's clients - www.castellum.us & www.tradewindsnetworks.com VIENNA, Va., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) (the “Compa ...

Core Viewpoint - First Quantum Minerals Ltd. announced the results of its cash tender offer for its outstanding 6.875% Senior Notes due 2027, with a total of $714,625,000 validly tendered and accepted for purchase [1][3]. Group 1: Tender Offer Details - The tender offer expired on August 18, 2025, with a deadline for guaranteed delivery set for August 20, 2025 [2]. - The total principal amount of Notes accepted for purchase is $714,625,000, which includes $6,503,000 tendered under guaranteed delivery procedures [3]. - The Notes Consideration is set at $1,003.79 for each $1,000 principal amount of Notes validly tendered and accepted [7]. Group 2: Financial Implications - Following the completion of the tender offer, the outstanding principal amount of the Notes will be reduced to $35,375,000 [4]. - The Company will pay the applicable Notes Consideration promptly after the expiration date, expected on August 21, 2025 [9]. - Holders who validly tender their Notes will receive accrued and unpaid interest up to the settlement date [9]. Group 3: Management and Contact Information - J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BMO Capital Markets Corp., and Société Générale are serving as dealer managers for the tender offer [11]. - For further inquiries, the Company has provided contact details for investor and media relations [12].

Core Insights - Teleflex Incorporated has launched Barrigel™ rectal spacer in Japan, following regulatory approval and insurance coverage acceptance, marking a significant step in its global expansion strategy [3][5][11] - Barrigel™ is the first and only sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer, designed to reduce radiation exposure to the rectum during prostate cancer treatment [4][9] - In 2022, prostate cancer was the most common cancer among men in Japan, with 104,318 new cases, representing 18% of all cancer diagnoses nationwide [5] Product Details - Barrigel™ rectal spacer has demonstrated a 98% success rate in achieving at least a 25% reduction in radiation to the rectum in a U.S. clinical study, with an average reduction of 85% in rectal V54 Gy radiation [6] - The product is indicated for prostate cancer patients with T1-T3b disease and is cleared for use in the U.S., Australia, Europe, and Japan [11][12] - Barrigel™ is made from biodegradable NASHA, which is biocompatible and fully absorbable, ensuring safety and efficacy in various medical applications [10][12] Market Impact - The launch in Japan is expected to enhance access to Barrigel™ for men undergoing prostate cancer radiation therapy, minimizing rectal side effects [7] - Teleflex aims to establish Barrigel™ as the standard of care for prostate cancer radiation therapy, emphasizing its innovative technology and precision in placement [5][8] - Training for healthcare professionals in Japan has commenced, led by top radiation oncologists, to ensure effective implementation of the product [8]

Core Insights - H World Group Limited is celebrating its 20th anniversary in 2025, having evolved from a single hotel brand to a multi-brand hospitality group with over 12,000 hotels across 19 countries [1] - The company will host its inaugural H World Capital Markets Day on October 30, 2025, in Shanghai, China, to outline its future strategic direction [1] Company Overview - As of March 31, 2025, H World operated 11,685 hotels with a total of 1,142,158 hotel rooms in 19 countries [3] - The company's brands include HanTing Hotel, JI Hotel, Orange Hotel, Crystal Orange Hotel, IntercityHotel, Hi Inn, Ni Hao Hotel, Elan Hotel, Zleep Hotels, Starway Hotel, CitiGo, Manxin Hotel, Madison Hotel, MAXX, Blossom House, Joya Hotel, Steigenberger Hotels & Resorts, Jaz in the City, Steigenberger Icon, and Song Hotels [3] - H World holds master franchise rights for Mercure, Ibis, and Ibis Styles, and co-development rights for Grand Mercure and Novotel in the pan-China region [3] Business Model - H World operates under leased and owned, manachised, and franchised models [4] - As of March 31, 2025, 8% of hotel rooms were operated under the lease and ownership model, while 92% were under the manachise and franchise model [4] - The company applies a consistent standard and platform across all its hotels [4]

Core Viewpoint - SFL Corporation Ltd. announced preliminary financial results for Q2 2025, reporting a net income of $1.5 million and a quarterly cash dividend of $0.20 per share, reflecting ongoing efforts to strengthen its charter backlog and improve operational efficiency [1][4][5]. Financial Performance - The company reported a net income of $1.5 million, equating to $0.01 per share for the second quarter [7]. - Charter hire received in the quarter totaled $194 million, with approximately 87% from shipping and 13% from energy [7]. - Adjusted EBITDA from consolidated subsidiaries was $104 million, with $97 million from shipping and $7 million from energy, plus an additional $8 million from associated vessel owning companies [7]. Strategic Actions - SFL has taken decisive steps to enhance its charter backlog by securing agreements with strong counterparties and investing in cargo-handling and fuel-efficiency upgrades [3]. - The company has divested older, less efficient vessels, which has improved the operational and fuel consumption efficiency of its fleet [3]. - A five-year time charter extension for three 9,500 TEU container vessels with Maersk is expected to add approximately $225 million to the backlog from 2026 through 2031 [7]. Dividend Information - The Board of Directors declared a quarterly cash dividend of $0.20 per share, to be paid on or around September 29, 2025, with a record date of September 12, 2025 [5][6]. - Since its inception in 2004, SFL has distributed a total of $2.9 billion to shareholders through 86 consecutive quarterly cash dividends [5]. Market Conditions - The market for the legacy drilling rig Hercules remains challenging due to recent market uncertainty and oil price volatility, which has delayed new employment opportunities [4]. - The company is optimistic about finding new employment for the rig while exploring strategic opportunities [4].

Core Insights - Willis, a WTW business, has launched Gemini, a digital facility aimed at providing sustainable capacity to clients' insurance portfolios, addressing risk complexity and market volatility [1][2] - Gemini offers a 2.5% discount on lead pricing and is supported by Lloyd's syndicates, enhancing client confidence in challenging conditions [2][5] - The service will be available exclusively to Willis clients for risks starting from September 1, 2025 [3] Features of Gemini - Gemini provides substantial capacity for any in-scope risk, regardless of complexity, ensuring competitive pricing and guaranteed discounts for clients [5] - The platform allows for auto-approval of up to 12.5% of whole placements following lead quotes, facilitating quick deployment of capacity [2][5] - Claims management is simplified by following lead claims settlements, reducing complexity for clients [5]

Core Insights - Corbion and Kuehnle AgroSystems (KAS) have formed a strategic partnership to develop and commercialize a natural astaxanthin sourced from non-GMO heterotrophic algae, aiming to provide a sustainable alternative to current astaxanthin sources [1][2][5] Group 1: Partnership Details - The partnership will focus on creating an esterified form of astaxanthin that is rich in the most bioavailable isomer, which will enhance antioxidant performance, stability, and fat solubility, targeting both human and animal nutrition markets [3][4] - Development and technical transfer have already commenced, with updates expected as the project progresses [6] Group 2: Company Backgrounds - Corbion is a sustainable ingredients company with annual sales of €1,332.0 million in 2024, specializing in lactic acid, food preservation solutions, and algae ingredients, and is listed on Euronext Amsterdam [7] - KAS is a biotechnology company focused on sustainable innovation through algae-derived products, utilizing patented "dark fermentation" processes to produce natural astaxanthin, which is essential for human nutrition and aquafeed [8][9]

Core Insights - NewHydrogen, Inc. has appointed Dr. Austin Morales to its UCSB Technology Team to enhance the development of its ThermoLoop technology, which aims to produce low-cost clean hydrogen using water and heat instead of electricity [1][4] Company Overview - NewHydrogen is focused on developing ThermoLoop, a novel technology that utilizes water and heat to generate the world's lowest cost clean hydrogen, addressing the limitations of current hydrogen production methods that rely on hydrocarbons [6][7] - The company is currently funding research at the University of California, Santa Barbara, to advance its thermochemical water splitting technology, which has been in development since August 2023 [4][6] Team and Expertise - Dr. Morales joins a team of experts including Dr. Philip Christopher, Dr. Justin Marlowe, Dr. Yikyeom Kim, Dr. Eric McFarland, and Mr. Sundar Narayanan, all of whom are working on cost-effective thermochemical processes [2][4] - Dr. Morales has a strong background in dynamic reactor operation and catalytic processes, with a Ph.D. from the University of Houston and multiple awards for his research excellence [3][4] Technology and Market Potential - The ThermoLoop technology aims to significantly reduce the cost of clean hydrogen production by utilizing heat from various sources, thereby bypassing the expensive electricity generation process that currently constitutes 73% of clean hydrogen costs [7] - The clean hydrogen economy is projected to have a market value of $12 trillion, highlighting the significant economic potential of NewHydrogen's innovations [7]

Core Viewpoint - China Medical System Holdings Limited (CMS) reported positive interim results for the first half of 2025, indicating successful strategic transformation with year-on-year growth in both revenue and profit [1][2][3] Financial Performance - Revenue for the six months ended June 30, 2025, was approximately RMB4.00 billion, a year-on-year increase of 10.8% [1] - If all medicines were directly sold by the company, revenue would be approximately RMB4.67 billion, reflecting an 8.9% year-on-year growth [1] - Net profit was approximately RMB0.93 billion, representing a 3.1% year-on-year increase [1] Strategic Transformation - CMS has emerged from the impact of National Volume-based Procurement (National VBP), with expectations for sustainable growth [2] - Revenue from key non-National VBP exclusive/branded products and innovative products reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue [2] - The company’s strategic upgrade has been confirmed through solid operating results and innovation outcomes [3] Innovation and Product Development - The "product innovation" strategy is a key growth engine, utilizing overseas licensing, domestic collaboration, and in-house R&D [4] - CMS has successfully commercialized five innovative drugs in China, with additional products expected to receive marketing approvals by 2025 [5] - The innovative pipeline includes several blockbuster candidates in late-stage clinical development, expected to be commercialized within the next one to three years [6] Market Expansion and Commercial Model Reform - CMS is advancing its "New Models" strategy, focusing on specialty therapeutic fields and expanding into new retail and media channels [10][11] - The company completed a secondary listing on the Main Board of the Singapore Exchange, marking a milestone in its internationalization strategy [12] - The skin health business, Dermavon, has shown strong potential and is proposed to be spun off for separate listing to unlock its value [11] Future Outlook - The growth logic of "New CMS" is expected to accelerate, improving profitability and performance resilience [13] - The company aims to deliver quality pharmaceutical products and services globally, generating sustainable returns for shareholders [13]